Physician profile
Jonathan David Cohen
NPI 1497915292
$4,119.55
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $143 · 2021: $287 · 2022: $1,829 · 2023: $484 · 2024: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,566.48 | 2022 | |
| Medical Device Business Services, INC. | $815.39 | 2019 | |
| Intersect Ent, INC. | $279.80 | 2019-2021 | |
| Glaxosmithkline, LLC. | $279.57 | 2021-2024 | Nucala |
| Regeneron Healthcare Solutions, INC. | $266.95 | 2021-2024 | Dupixent |
| Aerin Medical INC. | $234.97 | 2023-2024 | |
| Optinose US, INC. | $217.62 | 2019-2024 | |
| Stryker Corporation | $151.80 | 2020-2022 | |
| Acclarent, INC | $111.11 | 2021 | |
| Genzyme Corporation | $90.68 | 2023-2024 | |
| Covis Pharma Gmbh | $58.15 | 2020-2021 | |
| Medtronic, INC. | $17.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.